The Gavi Board:

a) **Appointed** the following members:

- **Sania Nishtar** as an Unaffiliated Board Member in the seat currently held by Wayne Berson effective 1 January 2016 and until 31 December 2018.

- **Edna Yolani Batres** of Honduras as Board Member representing the developing country constituency in the seat currently held by Andrei Usatii of Moldova effective 1 January 2016 and until 31 December 2018.

- **Raymonde Goudou Coffie** of Côte d’Ivoire as Board Member representing the developing country constituency in the seat currently held by Awa Marie Coll-Seck of Senegal effective 1 January 2016 and until 31 December 2018.
DECISION 1: BOARD/COMMITTEE MEMBER NOMINATIONS (2/10)

- **Ingrid-Gabriela Hoven** of Germany as Board Member representing the France, Luxembourg, European Commission, and Germany donor constituency in the seat currently held by Mariam Diallo of France effective 1 January 2016 and until 31 December 2016.

- **Samba O. Sow** as Board Member representing the Research and Technical Health Institutes constituency in the seat currently held by Zulfiqar A. Bhutta effective 1 January 2016 and until 31 December 2017.

b) **Reappointed** the following Board Members:

- **Richard Sezibera** as an Unaffiliated Board Member until 31 December 2018.

- **Angela Santoni** of Italy as Board Member representing the Spain and Italy donor constituency until 31 December 2016.
c) **Appointed** the following Alternate Board Members:

- **Sergey Khchatryan** of Armenia as Alternate Board Member to Edna Yolani Batres of Honduras representing the developing country constituency in the seat currently held by Bheri Ramsaran of Guyana effective 1 January 2016 and until 31 December 2018.

- **Felix Kabange** of the Democratic Republic of the Congo as Alternate Board Member to Raymonde Goudou Coffie of Côte d’Ivoire representing the developing country constituency in the seat currently held by Dorothée Kinde Gazard of Benin effective 1 January 2016 and until 31 December 2018.
DECISION 1: BOARD/COMMITTEE MEMBER NOMINATIONS (4/10)

- **Jan Paehler** of the European Commission as Alternate Board Member representing the France, Luxembourg, European Commission, and Germany donor constituency in the seat currently held by Marcus Koll of Germany effective 1 January 2016 and until 31 December 2016.

- **Bradford Gessner** as Alternate Board Member to Samba O. Sow representing the Research and Technical Health Institutes constituency in the seat currently held by Samba O. Sow effective 1 January 2016 and until 31 December 2017.

d) **Reappointed** the following Alternate Board Member:

- **Javier Hernández Peña** of Spain as Board Member representing the Spain and Italy donor constituency until 31 December 2016.
e) **Appointed** the following to the Executive Committee effective 1 January 2016:

- Ngozi Okonjo-Iweala (statutorily appointed)
- Flavia Bustreo (statutorily appointed)
- David Sidwell until 31 December 2017
- Orin Levine until 31 December 2017
- Geeta Rao Gupta until 31 December 2017
- Tim Evans until 31 December 2017
- Donal Brown until 1 July 2016
- Bahar Idriss Abugarda until 31 December 2017
- Seth Berkley (non-voting and statutorily appointed)
f) **Appointed** the following to the Audit and Finance Committee effective 1 January 2016:

- **David Sidwell** until 31 December 2017
- **Shanelle Hall** until 31 December 2017
- **Jo-Ann Purcell** until 1 July 2016
- **Katherine Taylor** until 30 June 2017
- **Marcus Koll** until 31 December 2017
- **François Lefebvre** until 31 December 2017
- **Clarisse Loe Loumou** until 30 June 2017
- **Heidi Malene Nipe** until 31 December 2017
g) **Appointed** the following to the Governance Committee effective 1 January 2016:

- **Flavia Bustreo** (statutorily appointed)
- **Gunilla Carlsson** until 31 December 2017
- **Orin Levine** until 31 December 2017
- **Donal Brown** until 1 July 2016
- **Blair Exell** until 30 June 2017
- **Eivind Homme** until 31 December 2016
- **Javier Hernández Peña** until 31 December 2016
- **Jan Paehler** until 31 December 2017
- **Naveen Thacker** until 30 June 2017
- **Laura Laughlin** until 31 July 2017
- **Kesetebirhane Admasu** until 31 December 2017
- **Samba O. Sow** until 31 December 2017
- **Seth Berkley** (non-voting)
DECISION 1: BOARD/COMMITTEE MEMBER NOMINATIONS (8/10)

h) **Appointed** the following to the Investment Committee effective 1 January 2016:
   - Stephen Zinser until 30 June 2017
   - William Roedy until 31 December 2017
   - David Sidwell until 31 December 2017
   - Yifei Li until 31 December 2017

i) **Appointed** the following to the Programme and Policy Committee effective 1 January 2016:
   - Richard Sezibera until 31 December 2017
   - Sania Nishtar until 31 December 2017
   - Jason Lane until 31 December 2017
   - Susan McKinney until 31 December 2017
   - Mariam Diallo until 31 December 2017
DECISION 1: BOARD/ COMMITTEE MEMBER NOMINATIONS (9/10)

- Lene Lothe until 31 December 2016
- Ahmed Jan Naeem until 31 December 2017
- Lindsey Dietschi until 31 December 2017
- Rajinder Suri until 31 December 2017
- Jean-Marie Okwo-Bele until 31 December 2017
- Robert Oelrichs until 31 December 2017
- Violaine Mitchell until 31 December 2017
- Zulfiqar A. Bhutta until 31 December 2017
- Robin Nandy until 31 December 2017
- Seif Seleman Rashid until 31 December 2017
- Shanta Bahadur Shrestha until 31 December 2017
- Edna Yolani Batres until 31 December 2017
- Dure Samin Akram until 31 December 2017
- Seth Berkley (non-voting)
j) **Appointed** the following to the Evaluation Advisory Committee effective 1 January 2016:

- **Angela Santoni** until 31 December 2016
- **Wieneke Vullings** until 31 December 2016
- **Samba O. Sow** until 31 December 2017
- **Fred Binka** until 31 December 2016
- **Gonzalo Hernández** until 31 December 2016
- **Zulfiqar A. Bhutta** until 31 December 2017
- **Jeanine Condo** until 31 December 2017
DECISION 2: COMMITTEE CHAIR NOMINATIONS

The Gavi Board:

a) **Appointed:**
   - **David Sidwell** as Chair of the Audit and Finance Committee effective 1 January 2016 and until 31 December 2017

b) **Reappointed:**
   - **Stephen Zinser** as Chair of the Investment Committee effective 1 January 2016 and until 30 June 2017
   - **Richard Sezibera** as Chair of the Programme and Policy Committee effective 1 January 2016 and until 31 December 2017

2 Board meeting 2-3 December 2015
DECISION 3: AMENDMENTS TO COMMITTEE CHARTERS

The Gavi Board:

a) **Approved** amendments to the Audit and Finance Committee Charter as outlined in Annex A to Doc 02c.

b) **Approved** amendments to the Programme and Policy Committee Charter as outlined in Annex B to Doc 02c.
DECISION 4: IRC NOMINATIONS

The Gavi Board:

- **Extended** the terms of the IRC members listed in Annex A of Doc 02d for a further three-year term until March 2019.
DECISION 5: PROGRAMME FUNDING POLICY

The Gavi Board:

- **Approved** the amended Gavi Programme Funding Policy attached as Annex A to Doc 02e.
DECISION 6: AUDIT AND INVESTIGATIONS TERMS OF REFERENCE

The Gavi Board:

- **Approved** the revised Audit and Investigations Terms of Reference attached as Annex A to Doc 02f.
The Gavi Board:

2016 Envelope for “unrestricted” countries

- **Approved** a 2016 Programme Funding Envelope for unrestricted countries from which the Secretariat, under the Programme Funding Policy, shall allot funding to programmes until 31 December 2016, to endorse or adjust previously endorsed amounts of programme multi-year budgets for existing programmes and new cash programmes for an aggregate amount not exceeding US$ 2,807 million. (These endorsements would constitute acknowledgement of such budget amounts at the time of allotment but would not constitute a funding approval, decision, obligation or commitment of the GAVI Alliance or its contributors.)
DECISION 7: FINANCIAL FORECAST & PROGRAMME FUNDING REQUEST (2/2)

The Gavi Board in session without the participation of US citizens and residents:

2016 Envelope for “restricted” countries

- **Approved** a 2016 Programme Funding Envelope for restricted countries from which the Secretariat, under the Programme Funding Policy, shall allot funding to programmes until 31 December 2016, to endorse or adjust previously endorsed amounts of programme multi-year budgets for existing programmes and new cash programmes for an aggregate amount not exceeding US$ 20 million. (These endorsements would constitute acknowledgement of such budget amounts at the time of allotment but would not constitute a funding approval, decision, obligation or commitment of the GAVI Alliance or its contributors.)
DECISION 8: MEASLES AND RUBELLA STRATEGY (1/2)

The Gavi Board:

a) **Approved** a comprehensive measles and rubella strategy for Gavi as set out in section B, 5.5-5.16 of Doc 10 to the PPC (the proposed “Measles and Rubella Strategy”), as amended by discussions at the PPC, and noting the additional funding for the current strategy period (2016-2020) amounts to approx. US$ 220 million.

b) **Noted** the importance of enhancing Gavi’s approach to supporting countries for measles and rubella, and **requested** the Secretariat and the Alliance partners to: (i) ensure Measles and Rubella Strategy is fully incorporated in the countries’ immunisation programmes and plans, (ii) implement through the use of already existing mechanisms such as the Joint Appraisals and High Level Review Panel, with any necessary modifications; and (iii) put in place mechanisms that better leverage strengths in the Alliance, in order to improve the planning, efficiency and effectiveness of campaigns.
c) **Noted** that the implication of the new strategy is that funding for the 2021-2025 period is estimated to be approx. US$ 500 million.
DECISION 9: ALLIANCE PARTNERSHIP STRATEGY WITH INDIA-2016-2021 (1/4)

The Gavi Board:

a) **Approved** the Gavi strategic partnership with India (the "India Partnership Strategy ") on a time-limited and catalytic basis as set out in Section 5 of Doc 08, including an indicative allocation of vaccines and cash support in Option 2 of Table 1 of Annex D to Doc 08 for a total estimated amount of up to US$ 500 million, using available resources from the Gavi 2016-2020 strategy period and targeted to accelerate vaccine introductions and improve coverage and equity.
b) **Requested** the Secretariat to work with the Government of India ("GoI") to develop an agreement or an appropriate equivalent to implement the India Partnership Strategy setting out how Gavi’s catalytic support will be used to accelerate the GoI’s introduction and scale-up of new vaccines (rotavirus, MR, pneumococcal and HPV) and to improve coverage and equity of immunisation. This agreement should define:

i. the final allocation of vaccines and cash support to be targeted to improving coverage and equity;

ii. key principles of Gavi support (to the extent these differ from the Partnership Framework Agreement) including milestones for the India Partnership Strategy, focus on equity and a framework for the GoI to provide regular updates;
iii. the process governing the application and approval process for vaccine and cash support for the GoI;

iv. commitments from the GoI to fund the balance of the costs of the relevant campaign(s) and/or introduction(s) and to sustain the programme(s) following the introduction(s) using domestic resources and fully exploring innovative and complementary financing mechanisms;

v. a “Partnership Framework” including performance milestones and indicators.
c) Recognising the importance of manufacturers based in India and the critically important role of the Government of India (“GoI”) in the procurement of vaccines for India’s children, successful collaboration around vaccine supply and procurement between Gavi and the GoI should contribute to enhance supply security and a sustainable supply base to maximise procurement outcomes for Gavi and the GoI: requested that the Gavi Secretariat and partners invite GoI to explore together how to share information and plan supply and procurement for vaccines in the GoI and Gavi portfolios and explore potential coordination to maximise the sustainability and affordability of vaccines with an initial report back to the PPC in October 2016 and to the Board in December 2016.

d) Request the Secretariat to provide a review of the developed agreement or appropriate equivalent in 2016 as well as regular updates on the implementation of the agreement or appropriate equivalent and a formal review in 2018 on the progress of the India Partnership Strategy to be considered by the PPC and the Board, as appropriate.
DECISION 10: GAVI ALLIANCE STRATEGY 2016-2020: GOAL LEVEL INDICATORS AND TARGETS

The Gavi Board:

a) **Approved** the indicators and targets for the Gavi Strategy 2016-2020 described in Section B of Doc 08 to the PPC, including Option 2 for the target reference group for the three immunisation coverage indicators endorsed by the Board in June 2015.

b) **Requested** the Secretariat to work with countries and other partners to further develop the operational details and targets for the integration, civil society and institutional capacity indicators and present them to the PPC for review.
DECISION 11: DATA STRATEGIC FOCUS AREA

The Gavi Board:

a) **Approved** the high-level approach to the strategic focus area ("SFA") on data for the 2016-2020 period as set out in Section B of Doc 06 to the PPC.

b) **Requested** the Secretariat to work with countries and other partners to operationalise the high-level approach in priority countries starting in 2016, and to ensure that submissions for funding through the PEF are consistent with this approach and the needs of priority countries.

c) **Requested** the Secretariat to ensure that the proportional distribution of PEF funds across data and the other five SFAs is rationalised once other SFAs are developed, and to present these distributions to the PPC in May 2016 to ensure strategic alignment with Gavi priorities.

d) **Requested** the Secretariat to ensure that strategic investments in data made through direct financial support to countries are consistent with the approach to the data SFA as well as with the outcomes of the review of Gavi’s model for direct financial support to countries.
The Gavi Board:

a) **Approved** within the overall envelope of US$ 169.3 million for 2016 and US$ 178.6 million for 2017 for the Partners’ Engagement Framework, the following allocation:

i. US$ 64.5 million in 2016 and US$ 69.5 million in 2017 for Targeted Country Assistance;

ii. US$ 26.0 million in 2016 and US$ 29.0 million in 2017 for Special Investments in Strategic Focus Areas, of which US$ 4 million per annum remains contingent on future Board approval of the relevant strategic approaches;

iii. US$ 19.6 million in 2016 and US$ 19.6 million in 2017 for UNICEF Supply Division for fees to implement vaccine and related supplies procurement under the 2016 and 2017 PEF;
iv. Up to US$ 3.3 million in 2016 and US$ 3.3 million in 2017 for UNICEF Supply Division for fees to implement cold chain equipment under the 2016 and 2017 PEF;

v. US$ 0.9 million in 2015, US$ 0.6 million in 2016 and US$ 0.5 million in 2017 for the World Bank to cover the shortfall in funding they have received from AMC investment income that is required under the AMC Stakeholders agreement to cover the Bank’s related administrative and commitment fees;

vi. US$ 18.9 million envelope in 2016 and US$ 20.4 million envelope in 2017 for impact assessments and evaluations to be administered by the Secretariat under the 2016 and 2017 PEF.
b) **Approved**, within the overall envelope of US$ 102.6 million in 2016 and US$ 108.6 million in 2017 for Secretariat Engagement, the following allocation:

i. US$ 102.4 million for the Secretariat operating expenses in 2016 and US$ 108.4 million for the Secretariat operating expenses in 2017

c) **Approved** US$ 2.6 million for a capital expenditure budget to implement the Secretariat’s part of the 2016 Gavi Engagement Framework (‘GEF’) and US$ 1.7 million for a capital expenditure budget to implement the Secretariat’s part of the 2017 GEF.
The Gavi Board:

a) **Noted** the commitments and significant steps taken by the Governments of Angola, Congo Republic and Ghana to pay their co-financing arrears for 2014 in full by the end of 2015.

b) **Reminded** countries that, in the event that their co-financing arrears are not paid in full on or before 31 January 2016, support for those vaccines for which co-financing arrears for 2014 remain after 31 January 2016 and Health Systems Strengthening support for countries will be suspended from 31 January 2016 until the co-financing arrears for 2014 are paid in full.
DECISION 14: EXECUTIVE COMMITTEE COMPOSITION (1/2)

The Gavi Board:

a) **Approved** the Executive Committee composition starting in 2016:
   - Unaffiliated – 2 seats
   - Donors – 2 seats
   - Developing countries – 2 seats
   - UNICEF, WHO, World Bank – 2 seats
   - Bill & Melinda Gates Foundation – 1 seat
   - Civil society organisations – 1 seat
   - CEO (not voting) – 1 seat

The following Board leadership positions shall be members of the Committee: Board Chair, Vice Chair, Audit and Finance Committee Chair, and Programme and Policy Committee Chair.

The Committee may exceptionally expand to 12 members if required to accommodate each of the Board leadership positions and each of UNICEF, WHO and the World Bank as founding members.
b) **Noting** that the net effect is that:

- Donors go from 1 seat to 2 seats
- Developing countries go from 1 to 2 seats
- CSOs obtain 1 seat
- Unaffiliates go from 4 seats (3 defined) to 2 defined seats
- Multilaterals go from 3 seats (2 defined) to 2 defined seats
- The Bill & Melinda Gates Foundation maintains one seat
- The CEO maintains one non-voting seat